Translating TRAIL-receptor targeting agents to the clinic

被引：66
作者：
den Hollander, Martha W. [1 ]
Gietema, Jourik A. [1 ]
de Jong, Steven [1 ]
Walenkamp, Annemiek M. E. [1 ]
Reyners, Anna K. L. [1 ]
Oldenhuis, Corina N. A. M. [1 ]
de Vries, Elisabeth G. E. [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9700 RB Groningen, Netherlands
来源：
CANCER LETTERS | 2013年 / 332卷 / 02期
关键词：
TRAIL; Clinical studies; Biomarkers; APOPTOSIS-INDUCING LIGAND; AGONISTIC MONOCLONAL-ANTIBODY; RECOMBINANT HUMAN APO2L/TRAIL; PHASE-I; FUSION PROTEIN; TUMOR-GROWTH; MAPATUMUMAB; COMBINATION; TRIAL; LEXATUMUMAB;
D O I：
10.1016/j.canlet.2012.04.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The extrinsic apoptotic pathway can be activated by the endogenous ligand TRAIL (Tumor Necrosis Factor (TNE)-Related Apoptosis-Inducing Ligand) by binding to the death receptors TRAIL-R1 and TRAIL-R2 on the cell surface. This pathway is currently evaluated as an anticancer treatment strategy. Both recombinant human TRAIL and several agonistic antibodies against TRAIL-R1 and R2 have been studied in single agent and combination studies and proved to be safe and well tolerated. In this article, the clinical studies published to date will be reviewed. Also, future perspectives and biomarker studies for selecting patients that will benefit from these agents will be discussed. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：194 / 201
页数：8
相关论文
共 73 条
  • [1] [Anonymous], 2011, J CLIN ONCOL S
  • [2] Safety and antitumor activity of recombinant soluble Apo2 ligand
    Ashkenazi, A
    Pai, RC
    Fong, S
    Leung, S
    Lawrence, DA
    Masters, SA
    Blackie, C
    Chang, L
    McMurtrey, AE
    Hebert, A
    DeForge, L
    Koumenis, IL
    Lewis, D
    Harris, L
    Bussiere, J
    Koeppen, H
    Shahrokh, Z
    Schwall, RH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) : 155 - 162
  • [3] Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).
    Belada, D.
    Mayer, J.
    Czuczman, M. S.
    Flinn, I. W.
    Durbin-Johnson, B.
    Bray, G. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR
    Bremer, E
    Samplonius, DF
    van Genne, L
    Dijkstra, MH
    Kroesen, BJ
    de Leij, LFMH
    Helfrich, W
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (11) : 10025 - 10033
  • [5] Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7
    Bremer, E
    Samplonius, DF
    Peipp, M
    van Genne, L
    Kroesen, BJ
    Fey, GH
    Gramatzki, M
    de Leij, LFMH
    Helfrich, W
    [J]. CANCER RESEARCH, 2005, 65 (08) : 3380 - 3388
  • [6] A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
    Camidge, D. Ross
    Herbst, Roy S.
    Gordon, Michael S.
    Eckhardt, S. Gail
    Kurzrock, Razelle
    Durbin, Blythe
    Ing, Josephine
    Tohnya, Tanyifor M.
    Sager, Jason
    Ashkenazi, Avi
    Bray, Gordon
    Mendelson, David
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (04) : 1256 - 1263
  • [7] Chawla S. P., 2010, J CLIN ONCOL S, V28
  • [8] Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4
    Chuntharapai, A
    Dodge, K
    Grimmer, K
    Schroeder, K
    Marsters, SA
    Koeppen, H
    Ashkenazi, A
    Kim, KJ
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (08) : 4891 - 4898
  • [9] Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
    Daniel, Dylan
    Yang, Becky
    Lawrence, David A.
    Totpal, Klara
    Balter, Inessa
    Lee, Wyne P.
    Gogineni, Alvin
    Cole, Mary J.
    Yee, Sharon Fong
    Ross, Sarajane
    Ashkenazi, Avi
    [J]. BLOOD, 2007, 110 (12) : 4037 - 4046
  • [10] First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study
    Demetri, George D.
    Le Cesne, Axel
    Chawla, Sant P.
    Brodowicz, Thomas
    Maki, Robert G.
    Bach, Bruce A.
    Smethurst, Dominic P.
    Bray, Sarah
    Hei, Yong-jiang
    Blay, Jean-Yves
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (04) : 547 - 563
12345678